Titus Ball - BGNE Old VP Officer
VP
Titus Ball is VP Officer of BGNE Old
| Age | 52 |
| Phone | 345-949-4123 |
| Web | https://www.beigene.com |
Titus Ball Latest Insider Activity
Tracking and analyzing the buying and selling activities of Titus Ball against BGNE Old stock is an integral part of due diligence when investing in BGNE Old. Titus Ball insider activity provides valuable insight into whether BGNE Old is net buyers or sellers over its current business cycle. Note, BGNE Old insiders must abide by specific rules, including filing SEC forms every time they buy or sell BGNE Old'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Titus Ball over six months ago Disposition of 137 shares by Titus Ball of BeiGene at 189.9413 subject to Rule 16b-3 | ||
Titus Ball over six months ago Acquisition by Titus Ball of 15340 shares of BeiGene at 12.23 subject to Rule 16b-3 |
BGNE Old Management Efficiency
The company has return on total asset (ROA) of (0.0958) % which means that it has lost $0.0958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2322) %, meaning that it created substantial loss on money invested by shareholders. BGNE Old's management efficiency ratios could be used to measure how well BGNE Old manages its routine affairs as well as how well it operates its assets and liabilities.BGNE Old currently holds 930.18 M in liabilities with Debt to Equity (D/E) ratio of 0.12, which may suggest the company is not taking enough advantage from borrowing. BGNE Old has a current ratio of 4.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BGNE Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | VP Age | ||
| Brian Mueller | Biomarin Pharmaceutical | 50 | |
| Brinda MD | Biomarin Pharmaceutical | 44 | |
| Mr MD | Incyte | N/A | |
| Elizabeth Reed | Travere Therapeutics | 53 | |
| George JD | Biomarin Pharmaceutical | 54 | |
| George Davis | Biomarin Pharmaceutical | 53 | |
| Nadia MBA | Arrowhead Pharmaceuticals | N/A | |
| James CPA | Apellis Pharmaceuticals | 58 | |
| Elaine Qian | Legend Biotech Corp | N/A | |
| Sandra Calvin | Travere Therapeutics | 59 | |
| Elizabeth JD | Travere Therapeutics | 54 | |
| Peter Rasmussen | Ascendis Pharma AS | 55 | |
| Laura Woodhead | Biomarin Pharmaceutical | 57 | |
| Mikhail JD | Vaxcyte | 43 | |
| Sheila JD | Incyte | 58 | |
Management Performance
| Return On Equity | -0.23 | |||
| Return On Asset | -0.0958 |
BGNE Old Leadership Team
Elected by the shareholders, the BGNE Old's board of directors comprises two types of representatives: BGNE Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BGNE. The board's role is to monitor BGNE Old's management team and ensure that shareholders' interests are well served. BGNE Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BGNE Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaodong Wang, CoChairman CoFounder | ||
| John Oyler, Chairman of the Board, CEO, Founder | ||
| Mi Zhou, Director Relations | ||
| Liza Heapes, Head Relations | ||
| Chan Lee, General VP | ||
| Wang Lai, Global RD | ||
| Kevin Mannix, VP Relations | ||
| Titus Ball, VP Officer | ||
| Julia Wang, Executive Officer | ||
| Aaron Rosenberg, CFO Officer | ||
| Jason Radford, Senior Development | ||
| Yang Ji, Chief Officer | ||
| Daniel Maller, VP Accounting | ||
| Jaspreet MD, Senior Strategy | ||
| Diana Francis, VP Compliance | ||
| Melika Davis, Clinical Head | ||
| Yan Qi, Senior China | ||
| Xiaobin Wu, President COO |
BGNE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BGNE Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.23 | |||
| Return On Asset | -0.0958 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.14) % | |||
| Current Valuation | 18.78 B | |||
| Shares Outstanding | 97.63 M | |||
| Shares Owned By Insiders | 19.43 % | |||
| Shares Owned By Institutions | 46.90 % | |||
| Number Of Shares Shorted | 1.38 M | |||
| Price To Earning | (16.19) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in BGNE Stock
If you are still planning to invest in BGNE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BGNE Old's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |